Fig. 1 · Structure

Documents & Downloads

Purvalanol B

Cat. No. A12352 CAS 212844-54-7

CDK inhibitor

Purvalanol B is a cyclin-dependent kinase inhibitor. IC50 values are 6, 6, 9, > 10,000, and 6 nM for cdc2/cyclin B, cdk2/cyclin A, cdk2/cyclin E, cdk4/cyclin D1 and cdk5-p35 respectively. Selective over a range of other protein kinases (IC50 > 10,000 nM).

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Target & Activity

Target Activity Value
cdc2/cyclin B IC50 6 nM
cdk2/cyclin A IC50 6 nM
CDK2/cyclinE IC50 9 nM
CDK5/p35 IC50 6 nM

Cellular Effect

Cell Line Activity Value Description Reference
MCF7 IC50 > 100 μM Antiproliferative activity against human MCF7 cells expressing estrogen receptor after 48 hrs by WST-1 assay [PMID: 21440449]
MDA-MB-231 IC50 > 100 μM Antiproliferative activity against estrogen receptor-deficient human MDA-MB-231 cells after 48 hrs by WST-1 assay [PMID: 21440449]

Purvalanol B Research Summary

This section summarizes 2 in vitro studies of Purvalanol B from 1 published reference. In vitro models include P. falciparum strain W2; synchronized blood stage cultures of P. falciparum.

Purvalanol B In Vitro Studies

Purvalanol B treatment of P. falciparum strain W2 cultures produced a reported fold change of 2.1 for proteasome component C8. In synchronized blood stage cultures of P. falciparum, Purvalanol B treatment produced a reported fold change of 5.1 for thioredoxin reductase 2. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Proteasome component C8 response in P. falciparum cultures

Cell-based study · P. falciparum strain W2 [1]

P. falciparum strain W2 cultures treated with Purvalanol B showed a reported fold change of 2.1 for proteasome component C8.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Proteasome component C8protein fold change 3× the IC50 concentration; 12 hours: Fold change: 2.1[1]

Literature-Reported Treatment Conditions

Exposure duration
At 24 hours post invasion
Method
applied to cultures
Vehicle
DMSO
Reported limits
Concentration removed by unit check.
Methods and source locations

Compound reported in the paper: Purvalanol B

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Methods > SYBR® Green I parasite growth assay (S9); Methods > Culturing parasites with Purvalanol B (S23, S25); Table 1 legend (S116); Table 1 (T1.h1, T1.r1)

Proteasome component C8: Proteasome component C8; comparator: DMSO vehicle only for 12 hours — Methods > Culturing parasites with Purvalanol B (S23); Table 1 (T1.h1, T1.r1)

Thioredoxin reductase 2 response in synchronized parasite cultures

Cell-based study · Synchronized blood stage cultures of P. falciparum [1]

Synchronized blood stage cultures of P. falciparum treated with Purvalanol B showed a reported fold change of 5.1 for thioredoxin reductase 2.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Thioredoxin reductase 22 ΔΔCT Fold change 3X the IC50 concentration; 12 hours: 2 ΔΔCT Fold change: 5.1[1]

Literature-Reported Treatment Conditions

Treatment concentration
3X the IC50 concentration
Exposure duration
at 24 hours post-invasion were treated with 3X the IC50 concentration of Purvalanol B and allowed to incubate for a further 12 hours
Vehicle
DMSO
Reported limits
Not stated in the sentences used: route.
Methods and source locations

Compound reported in the paper: Purvalanol B

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Methods > Culturing parasites with Purvalanol B (S23, S25); Results > Quantitative real-time RT-PCR (S93); Table 2 legend (S117); Table 2 (T2.h1, T2.r4)

Thioredoxin reductase 2: Thioredoxin reductase 2; comparator: DMSO vehicle only for 12 hours — Results > Quantitative real-time RT-PCR (S93); Table 2 (T2.h1, T2.r4)

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 212844-54-7
Applications CDK inhibitor
Formula C20H25ClN6O3
Molecular Weight 432.91
Synonyms NG 95
SMILES
CC(C)[C@H](CO)NC1=NC2=C(C(=N1)NC3=CC(=C(C=C3)C(=O)O)Cl)N=CN2C(C)C

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 84 mg/mL (194.04 mM)
Water <1 mg/mL
Ethanol <1 mg/mL

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Purvalanol B Research References

  1. [1] Bullard KM, Broccardo C, Keenan SM. Effects of cyclin-dependent kinase inhibitor Purvalanol B application on protein expression and developmental progression in intra-erythrocytic Plasmodium falciparum parasites. Malar J (2015). PMID: 25879664 DOI: 10.1186/s12936-015-0655-x Source material

Added to your cart

View Cart Checkout
Loading...